DrugPatentWatch Database Preview
Drugs in Development Information for Poziotinib
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Poziotinib?
Poziotinib is an investigational drug.
There have been 18 clinical trials for Poziotinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2013.
The most common disease conditions in clinical trials are Breast Neoplasms, Adenocarcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, and National OncoVenture.
There are six US patents protecting this investigational drug and one hundred and seventeen international patents.
Summary for Poziotinib
| US Patents | 6 |
| International Patents | 117 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-01-01) |
| Vendors | 56 |
Recent Clinical Trials for Poziotinib
| Title | Sponsor | Phase |
|---|---|---|
| Study of Poziotinib in Japanese Patients With NSCLC | Spectrum Pharmaceuticals, Inc | Phase 1/Phase 2 |
| Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects | Spectrum Pharmaceuticals, Inc | Phase 1 |
| A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Spectrum Pharmaceuticals, Inc | Phase 2 |
Clinical Trial Summary for Poziotinib
Top disease conditions for Poziotinib
Top clinical trial sponsors for Poziotinib
US Patents for Poziotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Poziotinib | Start Trial | Amide derivative for inhibiting the growth of cancer cells | Hanmi Holdings Co., Ltd. (Seoul, KR) | Start Trial |
| Poziotinib | Start Trial | Method for EGFR directed combination treatment of non-small cell lung cancer | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | Start Trial |
| Poziotinib | Start Trial | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pi- peridin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein | Hanmi Science Co., Ltd (Hwaseong-si, KR) | Start Trial |
| Poziotinib | Start Trial | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pi- peridin-1-yi)prop-2-en-1-one | Hanmi Pharm. Co., Ltd. (Gyeonggi-do, KR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Poziotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Poziotinib | Argentina | 066876 | 2027-06-05 | Start Trial |
| Poziotinib | Argentina | 110003 | 2027-06-05 | Start Trial |
| Poziotinib | Australia | 2008260772 | 2027-06-05 | Start Trial |
| Poziotinib | Brazil | PI0811069 | 2027-06-05 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
